Position in LLY
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$1,126,264
+$322,386 QoQ
Shares Held
939
+7.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.53%
of 13F equity value
Holder Rank
#3,027
of 4,605 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Purkiss Capital Advisors LLC holds $8,883,228 across 7 Drug Manufacturers - General names. LLY ranks #3 (12.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
13,798 | $3,504,278 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
36,627 | $2,110,447 | |
| 3 | LLY |
ELI LILLY & Co
This page
|
939 | $1,126,264 | |
| 4 | ABBV |
AbbVie Inc.
|
4,355 | $1,095,892 | |
| 5 | MRK |
Merck & Co., Inc.
|
3,751 | $482,003 | |
| 6 | AMGN |
Amgen Inc
|
898 | $325,183 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
1,893 | $239,161 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,126,264 | 939 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $803,878 | 874 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $916,702 | 853 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $688,226 | 902 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $808,372 | 1,037 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $474,898 | 575 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $452,392 | 586 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||